Davidson Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.26M Buy
+16,272
New +$4.17M 0.7% 43
2024
Q1
– Sell
-54
Closed -$8.37K – 95
2023
Q4
$8.37K Buy
+54
New +$7.87K ﹤0.01% 73
2023
Q2
– Sell
-9,664
Closed -$1.54M – 84
2023
Q1
$1.54M Sell
9,664
-44
-0.5% -$6.73K 0.94% 15
2022
Q4
$1.57M Sell
9,708
-34
-0.3% -$5.21K 1.08% 11
2022
Q3
$1.31M Buy
9,742
+745
+8% +$107K 0.64% 18
2022
Q2
$1.38M Sell
8,997
-23
-0.3% -$3.52K 0.65% 11
2022
Q1
$1.46M Sell
9,020
-2,558
-22% -$372K 0.55% 23
2021
Q4
$1.57M Buy
11,578
+371
+3% +$43.8K 0.86% 21
2021
Q3
$1.21M Buy
11,207
+398
+4% +$45.5K 0.61% 53
2021
Q2
$1.22M Buy
10,809
+103
+1% +$11.6K 0.59% 53
2021
Q1
$1.16M Buy
+10,706
New +$1.15M 0.61% 44

Other funds holding ABBV

Davidson Capital Management's ABBV Position: Q3 2026 in Review

Davidson Capital Management opened a new position in AbbVie (ABBV) in Q3 2026: 16,272 shares worth $4.26M. The stake represents 0.7% of the portfolio and ranks #43 among its holdings. This is a return to the name: Davidson Capital Management previously reported a position in ABBV as recently as Q4 2023.

Davidson Capital Management first reported a position in ABBV in Q1 2021 and has held it in 11 quarters since. 1,958 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Davidson Capital Management held 16,272 shares of AbbVie worth $4.26M as of Q3 2026.
  • AbbVie was a new Davidson Capital Management position in Q3 2026.
  • AbbVie made up 0.7% of Davidson Capital Management's portfolio in Q3 2026, its #43 holding.
  • Davidson Capital Management first reported a position in AbbVie in Q1 2021 and has held it in 11 quarters since.
  • 1,958 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Davidson Capital Management's 13F filing for Q3 2026, filed 15 Oct 2026.